Immunic (NASDAQ:IMUX) Upgraded to “Strong-Buy” at EF Hutton Acquisition Co. I

EF Hutton Acquisition Co. I upgraded shares of Immunic (NASDAQ:IMUX) to a strong-buy rating in a report issued on Monday, Zacks.com reports.

A number of other research firms have also recently issued reports on IMUX. Leerink Partners restated an outperform rating and set a $5.00 target price on shares of Immunic in a research note on Monday, September 9th. StockNews.com upgraded Immunic from a sell rating to a hold rating in a report on Tuesday, August 13th. Leerink Partnrs upgraded Immunic to a strong-buy rating in a research note on Monday, September 9th. B. Riley initiated coverage on Immunic in a research note on Tuesday, August 27th. They issued a buy rating and a $6.00 price target for the company. Finally, Piper Sandler reiterated an overweight rating and set a $28.00 price objective on shares of Immunic in a research report on Tuesday, July 16th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Immunic presently has an average rating of Buy and a consensus price target of $11.20.

Immunic Stock Up 8.9 %

NASDAQ:IMUX opened at $1.95 on Monday. Immunic has a 12-month low of $0.95 and a 12-month high of $2.11. The stock’s 50 day moving average price is $1.44 and its two-hundred day moving average price is $1.32. The firm has a market capitalization of $175.65 million, a price-to-earnings ratio of -1.07 and a beta of 1.82.

Immunic (NASDAQ:IMUX) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.02. During the same period in the prior year, the firm posted ($0.54) earnings per share. Equities research analysts expect that Immunic will post -0.92 EPS for the current year.

Hedge Funds Weigh In On Immunic

A number of hedge funds have recently added to or reduced their stakes in IMUX. Virtu Financial LLC bought a new stake in shares of Immunic during the 1st quarter worth approximately $25,000. Sierra Summit Advisors LLC acquired a new position in Immunic during the fourth quarter valued at approximately $487,000. Ikarian Capital LLC lifted its stake in Immunic by 258.3% during the first quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock worth $2,128,000 after purchasing an additional 1,162,378 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Immunic by 100.7% in the 1st quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock valued at $4,480,000 after purchasing an additional 1,703,047 shares in the last quarter. Finally, Janus Henderson Group PLC bought a new position in shares of Immunic in the 1st quarter valued at $9,266,000. Institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.